Just the day after we met, the Wall Street Journal had an editorial by Richard Epstein on the need to give cancer patients access to more potential treatments.
Epstein writes that "No one thinks that unapproved cancer drugs should be freely available to patients in the over-the-counter market. Yet once a drug passes Phase I clinical trials -- which test for high toxicity -- why not make it available for general distribution through the NCCN, which has far superior access to specialized medical expertise than the FDA?"
The NCCN is the National Comprehensive Cancer Network. One can imagine a similar set up for many other diseases. Epstein also argues on behalf of off label us of approved drugs.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment